Meeting
2012 ASCO Annual Meeting
A phase I clinical trial of autologous, anti-CD19 gene targeted T cells for adults with B cell acute lymphoblastic leukemia (B-ALL).
Authors
Marco L. Davila
Memorial Sloan-Kettering Cancer Center, New York, NY
Marco L. Davila , Isabelle Riviere , Xiuyan Wang , Shirley Bartido , Jolanta Stefanski , Clare Taylor , Malgorzata Olszewska , Oriana Borquez-Ojeda , Jinrong Qu , Teresa Wasielewska , Mark G. Frattini , Michel Sadelain , Renier J. Brentjens
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01044069
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS2619)
DOI
10.1200/jco.2012.30.15_suppl.tps2619
Abstract #
TPS2619
Poster Bd #
11D
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells.
First Author: Kristen Fousek
Poster
2014 ASCO Annual Meeting
Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.
First Author: Jae Hong Park
Poster
2022 ASCO Annual Meeting
STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
First Author: Navin R. Pinto
Poster
2019 ASCO Annual Meeting
A phase I trial using CD19 CAR-T expressing PD-1/CD28 chimeric switch-receptor for refractory or relapsed B-cell lymphoma.
First Author: Hui Liu